Related Experiment Video
Updated: May 21, 2025
03:54
A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance
Published on: October 19, 2018
6.1K
A novel self-assembling peptide as new submucosal injection solution in endoscopic submucosal dissection
Kenichiro Okimoto1, Tomoaki Matsumura2, Tsubasa Ishikawa2
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan. okimoto-k@chiba-u.jp.
Surgical Endoscopy
|March 20, 2025
Summary
PuraLift, a peptide-based solution for endoscopic submucosal dissection (ESD), provides similar lifting satisfaction to MucoUp but with reduced injection firmness. This makes PuraLift a viable alternative for ESD procedures.
Area of Science:
- Gastroenterology
- Surgical Innovation
- Biomaterials Science
Background:
- Endoscopic submucosal dissection (ESD) requires effective submucosal lifting solutions.
- PuraLift is a novel self-assembling peptide-based solution for submucosal injection.
- This study compares PuraLift to MucoUp in ESD procedures across multiple organs.
Purpose of the Study:
- To evaluate the effectiveness of PuraLift as a submucosal injection solution in ESD.
- To compare PuraLift's performance against MucoUp in terms of lifting, injection characteristics, and procedure efficiency.
- To assess endoscopist satisfaction with PuraLift in ESD.
Main Methods:
- A comparative study involving 40 consecutive ESD lesions (19 PuraLift, 21 MucoUp).
- Exclusion of complex cases (e.g., ulcerative colitis, fibrosis, circumferential lesions) and non-waterjet devices.
- Assessment of submucosal lifting satisfaction and injection firmness using a 5-point scale.
Main Results:
- PuraLift demonstrated significantly lower injection firmness across esophagus, stomach, and colon/rectum compared to MucoUp (p < 0.001).
- No significant differences were observed in endoscopist satisfaction, injected volume, glycerol use, or procedure time between PuraLift and MucoUp.
- PuraLift's mechanism resulted in less resistance during injection.
Conclusions:
- PuraLift offers comparable submucosal lifting satisfaction to MucoUp in ESD.
- The reduced injection firmness of PuraLift presents a potentially advantageous characteristic.
- PuraLift is a promising alternative submucosal injection solution for ESD procedures.
